menu
    • menu

    Company profile for Mira Pharmaceuticals

    NEW Drugs in Dev: 4
    Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

    Virtual Booth

    Contact Supplier

    Evonik Health Care is the innovation hub for leading life science companies

    Virtual Booth

    Contact Supplier

    Aarti Pharmalabs is a partner of choice for pharmaceutical companies for APIs & Intermediates. Largest Indian producer of Caffeine.

    Virtual Booth

    Contact Supplier

    Axplora is your partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Mira Pharmaceuticals Inc is an early pre-clinical-stage pharmaceutical company focused on the development and commercialization of a new molecular synthetic THC analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. MIRA1a is being developed as the first prescription drug to target the CB1 and CB2 receptors for chronic pain and anxiety w...
    Mira Pharmaceuticals Inc is an early pre-clinical-stage pharmaceutical company focused on the development and commercialization of a new molecular synthetic THC analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. MIRA1a is being developed as the first prescription drug to target the CB1 and CB2 receptors for chronic pain and anxiety without the impurities of marijuana or its side effects, such as increased appetite and paranoia.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Mira PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    855 N Wolfe St, Ste 601.2
    Telephone
    Telephone
    +1 8138642562
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://mirapharmaceuticals.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/mira-pharmaceuticals-inc/?viewAsMember=true
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/MediaRe05844504

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    BioProcess International US West

    Not Confirmed

    envelop Contact Supplier

    BioProcess International US West

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    MIRA Pharmaceuticals Completes Phase 1 Dosing Of Ketamir-2
    MIRA Pharmaceuticals Completes Phase 1 Dosing Of Ketamir-2

    04 Mar 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-03-04/mira-pharmaceuticals-completes-phase-1-dosing-of-ketamir-2

    PHARMIWEB
    04 Mar 2026
    Share Share
    MIRA Pharma Progresses Ketamir-2 To Phase 1 MAD Study
    MIRA Pharma Progresses Ketamir-2 To Phase 1 MAD Study

    29 Oct 2025

    // INDPHARMAPOST

    https://www.indianpharmapost.com/clinical-trials/mira-pharmaceuticals-advances-oral-ketamir-2-into-phase-1-mad-study-for-chemotherapy-induced-neuropathic-pain-18091

    INDPHARMAPOST
    29 Oct 2025
    Share Share
    MIRA Starts Ph1 Study of Ketamir-2 for Neuropathic Pain
    MIRA Starts Ph1 Study of Ketamir-2 for Neuropathic Pain

    24 Oct 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-10-24/mira-pharmaceuticals-initiates-multiple-ascending-dose-mad-phase-1-study-of-oral-ketamir-2-and-sel

    PHARMIWEB
    24 Oct 2025
    Share Share
    Mira Pharma Acquires Skny Pharma, Expands Pipeline With Skny-1
    Mira Pharma Acquires Skny Pharma, Expands Pipeline With Skny-1

    30 Sep 2025

    // ACCESSWIRE

    https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/mira-pharmaceuticals-closes-acquisition-of-skny-pharmaceuticals-expan-1079783

    ACCESSWIRE
    30 Sep 2025
    Share Share
    Mira Pharma Reports Positive Phase 1 Results For Oral Ketamir-2
    Mira Pharma Reports Positive Phase 1 Results For Oral Ketamir-2

    22 Sep 2025

    // PHARMAWEB

    https://www.pharmiweb.com/press-release/2025-09-22/mira-pharmaceuticals-announces-favorable-topline-results-from-phase-1-sad-study-of-oral-ketamir-2-a

    PHARMAWEB
    22 Sep 2025
    Share Share
    MIRA Pharma Reports Positive PTSD Data For Ketamir-2 In Animals
    MIRA Pharma Reports Positive PTSD Data For Ketamir-2 In Animals

    16 Sep 2025

    // PHARMAWEB

    https://www.pharmiweb.com/press-release/2025-09-16/mira-pharmaceuticals-reports-positive-ptsd-data-demonstrating-ketamir-2-restores-normalized-behavior

    PHARMAWEB
    16 Sep 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search